Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: new IRA concerns and legal action in the US; Biogen brings in another ex-Sanofi exec; Novartis buys into kidney disease; and China appears to be raising the regulatory bar in the immune-oncology space.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 16 June 2023, including: new IRA concerns and legal action in the US; Biogen, Inc. brings in another ex-Sanofi exec; Novartis AG buys into kidney disease; and China appears to be raising the regulatory bar in the immune-oncology space.

This and all our other podcasts are available on the Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode: 

(Also see "Lilly Sidelined Three Drugs Due To IRA, CEO Ricks Says" - Scrip, 14 Jun, 2023.)

(Also see "What To Expect As IRA Legal Challenges Mount" - Scrip, 12 Jun, 2023.)

(Also see "Biogen’s Adam Keeney Focuses On Dealmaking As Growth Strategy Is Made Over" - Scrip, 13 Jun, 2023.)

(Also see "Novartis Aims To Fly High In Kidney Disease With Chinook Buy" - Scrip, 12 Jun, 2023.)

(Also see "Chinese Regulator Rejects Domestic PD-1/L1 Contender In Latest Tightening Signal" - Scrip, 14 Jun, 2023.)

 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel